On June 21, Axinn partners Aziz Burgy and Jason Murata will speak at American Conference Institute's Summit on Biosimilars and Innovator Biologics, being held June 20-21 in New York.

Aziz will speak on the "Reviewing Cases and Distilling Trends: The Key Federal and District Court Lawsuits Shaping the BPCIA Landscape" panel. Panelists will discuss:

• Regeneron’s BPCIA litigation against Celltrion, Samsung Bioepis, Formycon, and Mylan for each of their proposed biosimilars of EYLEA;
• Regeneron’s motion to establish multi-district litigation encompassing the aflibercept BPCIA cases and;
• The latest biologic and biosimilar patent litigation strategies.

Jason will speak on the "Diversity, Equity, and Inclusion in the Research, Development, and Approval of Biologics and Biosimilars" panel. Panelists will discuss:

• Navigating corporate buy-in for DEI in company culture and practice amidst state legislature and political pressures advocating against DEI implementation;
• Encouraging diversity and inclusion in innovation;
• Exploring the consequences of biased data sets in clinical research and the importance of diversity in research and;
• Promoting diversity, equity, and inclusion in legal practice. Click here for more information, including how to register.

Click here for more information, including how to register.